Gene · 574452
Papers2,094
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,094
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunometabolic reprogramming, another cancer hallmark. | Front Immunol | 2023 | 37275901 | PubTator, text mining | PubMed |
| Development and validation of an oxidative stress‑related prognostic signature in osteosarcoma: A combination of molecular experiments and bioinformatics. | Oncol Lett | 2023 | 37274481 | PubTator, text mining | PubMed |
| Acute Kidney Injury in Kidney Transplant Patients in Intensive Care Unit: From Pathogenesis to Clinical Management. | Biomedicines | 2023 | 37239144 | PubTator, text mining | PubMed |
| Role of telomere length in human carcinogenesis (Review). | Int J Oncol | 2023 | 37232367 | PubTator, text mining | PubMed |
| Retraction Notice to: MicroRNA-494 Inhibits the LRG1 Expression to Induce Proliferation and Migration of VECs in Rats following Myocardial Infarction. | Mol Ther Nucleic Acids | 2023 | 37215151 | PubTator, text mining | PubMed |
| The mechanisms and diagnostic potential of lncRNAs, miRNAs, and their related signaling pathways in cervical cancer. | Front Cell Dev Biol | 2023 | 37215076 | PubTator, text mining | PubMed |
| hsa‑miR‑216a‑3p regulates cell proliferation in oral cancer via the Wnt3a/β‑catenin pathway. | Mol Med Rep | 2023 | 37203400 | PubTator, text mining | PubMed |
| Cell-Based Therapies for Degenerative Musculoskeletal Diseases. | Adv Sci (Weinh) | 2023 | 37199688 | PubTator, text mining | PubMed |
| MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes. | Cancers (Basel) | 2023 | 37190222 | PubTator, text mining | PubMed |
| Retraction notice to "MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome" [Life Sci. 210 (2018) 1-8]. | Life Sci | 2023 | 37179192 | PubTator, text mining | PubMed |
| The Role of NAD+, SIRTs Interactions in Stimulating and Counteracting Carcinogenesis. | Int J Mol Sci | 2023 | 37175631 | PubTator, text mining | PubMed |
| Abscopal Effect, Extracellular Vesicles and Their Immunotherapeutic Potential in Cancer Treatment. | Molecules | 2023 | 37175226 | PubTator, text mining | PubMed |
| Biomolecules Involved in Both Metastasis and Placenta Accreta Spectrum-Does the Common Pathophysiological Pathway Exist? | Cancers (Basel) | 2023 | 37174083 | PubTator, text mining | PubMed |
| Spatiotemporal Coordination of RPE Cell Quality by Extracellular Vesicle miR-494-3p Via Competitive Interplays With SIRT3 or PTEN. | Invest Ophthalmol Vis Sci | 2023 | 37163276 | PubTator, text mining | PubMed |
| Downregulation of microRNA‑494 inhibits cell proliferation in lung squamous cell carcinoma via the induction of PUMA‑α‑mediated apoptosis. | Exp Ther Med | 2023 | 37153893 | PubTator, text mining | PubMed |
| Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer. | Front Immunol | 2023 | 37153619 | PubTator, text mining | PubMed |
| The roles of EZH2 in cancer and its inhibitors. | Med Oncol | 2023 | 37148376 | PubTator, text mining | PubMed |
| Increased serum extracellular vesicle miR-144-3p and miR-486a-3p in a mouse model of adipose tissue regeneration promote hepatocyte proliferation by targeting Txnip. | PLoS One | 2023 | 37141242 | PubTator, text mining | PubMed |
| Circular RNA EPHA3 suppresses progression and metastasis in prostate cancer through the miR-513a-3p/BMP2 axis. | J Transl Med | 2023 | 37118847 | PubTator, text mining | PubMed |
| Computational Analysis Reveals Distinctive Interaction of miRNAs with Target Genes in the Pathogenesis of Chronic Kidney Disease. | Genes (Basel) | 2023 | 37107656 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/574452/papers?page=8